What Investors Are Missing With GlaxoSmithKline plc

GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) shares have been hammered since the company said it would post no sales or profit growth in the year ahead after all, but what is much more important for the long term is the reshaping taking place — and the new drugs coming down the line…

GlaxoSmithKline is one of five shares in the FTSE 100 that our top analysts have highlighted in our special report "5 Shares To Retire On". To find out the reasons behind their inclusion, and the names of the other four shares, simply click here to have it delivered completely free to your inbox.

Owain Bennallack has no position in any shares mentioned. The Motley Fool recommends GlaxoSmithKline.